Heme/Onc Qs Flashcards
Findings diagnostic of paroxysmal nocturnal hemoglobinuria? (including cell markers)
hemolytic anemia, hypocellular bone marrow, and lack of CD55 and CD59.
idiopathic Bud-Chiari syndrome - test for?
JAK2 mutation
t(9;22)? Treat with?
Philadelphia chromosome. Dasatintib or the imiatinib
HLA-matched platelets would only be used if?
Washing of platelets is reserved for?
history of platelet transfusion refractoriness attributed to platelet alloantibodies
history of a severe allergic reaction (anaphylaxis) to a transfused blood product
Parvovirus B19 infection in sickle cell can present with?
pure red cell aplasia
essential thrombocythemia - treatment? Who gets it?
Hydroxyurea plus low-dose aspirin
Patients older than 60 years, platelet count greater than 1 million/µL, or those with a history of thrombosis.
G6PD stain?
cresyl blue
cryoprecipitate is typically reserved for?
significant bleeding and a fibrinogen level less than 100 mg/dL
Cold agglutinin disease can be confirmed with?
Coombs test
Risk factors for progression of monoclonal gammopathy of undetermined significance to multiple myeloma?
non-IgG M protein, an M protein level of at least 1.5 g/dL, and an abnormal serum free light chain ratio
Discrepancy between urine dip stick (albumin) and Urine protein ratio suggest?
monoclonal FLCs in the urine (Bence-Jones proteinuria) and potential cast nephropathy
classic presentation for CML ?
smear shows?
fatigue; early satiety and progressive weight loss associated with splenomegaly; and a peripheral blood smear demonstrating myelocytes, metamyelocytes, and basophils
IGH/CD1 is the mutation associated with?
PML-RAR protein mutation is associated with?
Mantle cell lymphoma
acute promyelocytic leukemia (APL)
acute promyelocytic leukemia (APL) is clinically associated with?
DIC and thrombocytopenia and NO SPLENOMEGALY
Surgery Hgb goal for sickle cell?
10
Parenteral anticoagulant administration must overlap with warfarin for?
5 days and INR>2 for 24 hours
5-Azacytidine is appropriate therapy for? Why?
higher risk MDS for the purpose of improving blood counts, delaying AML progression, and extending survival.